20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
Shares of Geron (NASDAQ:GERN) remained unaffected after the company reported Q3 results.
Quarterly Results
Earnings per share increased 25.00% over the past year to ($0.06), which were in line with the estimate of ($0.06).
Revenue of $108,000 decreased by 17.56% year over year, which beat the estimate of $40,000.
Guidance
Geron hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: Nov 05, 2020
Time: 04:30 PM
ET Webcast URL: http://www.directeventreg.com/registration/event/7879966
Recent Stock Performance
52-week high: $2.40
Company's 52-week low was at $0.75
Price action over last quarter: Up 10.71%
Company Description
Geron Corp is a clinical stage biopharmaceutical company focused on research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses the global rights to this drug.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!